Modern Healthcare Technology Holdings Limited (0919) AI Stock Analysis

• Market Cap: €89.54M
• Dividend Yield: N/A
• Average Volume (3M): 278.13K
• Price to Earnings (P/E): 24.4
• Beta (1Y): 0.01
• Revenue Growth: -0.31%
• EPS Growth: 47.17%
• Country: HK
• Employees: 850
• Sector: Consumer Cyclical
• Sector Strength: 73
• Industry: Personal Products & Services
• EPS (TTM): 0.01
• Shares Outstanding: 904,483,950
• 10 Day Avg. Volume: 308,800
• 30 Day Avg. Volume: 278,133
• PEG Ratio: 0.28
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.15
• P/FCF Ratio: 0.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by the company's financial performance challenges, including declining revenue and profitability. However, positive technical indicators provide some optimism. The valuation is weak due to a negative P/E ratio and lack of dividend yield.

Modern Healthcare Technology Holdings Limited Business Overview & Revenue Model

Company Description

Modern Healthcare Technology Holdings Limited (0919) is a company focused on providing innovative healthcare technology solutions. Operating primarily within the healthcare sector, the company develops and offers a range of products and services that enhance patient care, streamline healthcare operations, and improve overall healthcare delivery. Its offerings may include digital health platforms, medical software, and other technology-driven solutions designed to meet the evolving needs of healthcare providers and patients alike.

How the Company Makes Money

The company generates revenue through multiple streams, primarily by selling its healthcare technology products and services to hospitals, clinics, and other healthcare facilities. This includes software licensing fees, subscription services for ongoing support, and maintenance contracts. Additionally, Modern Healthcare Technology Holdings Limited may engage in partnerships with other technology firms and healthcare organizations, leading to collaborative projects that can enhance its service offerings and increase revenue. The company may also benefit from government contracts or grants aimed at improving healthcare technology infrastructure, further contributing to its financial growth.

Modern Healthcare Technology Holdings Limited Financial Statement Overview

Summary

The company shows revenue growth and a stable balance sheet but faces profitability issues with continuous net losses. While cash flow management is strong, the decline in free cash flow growth suggests a need for improved margin and profitability.

Income Statement

The company's revenue has shown growth over the past year, increasing by 11.9% from 2023 to 2024. However, profitability is a concern as net income remains negative, reflecting a -2.1% net profit margin in 2024. Gross profit margin improved to 16.8%, but EBIT and EBITDA margins are low at 2.1% and 21% respectively, indicating operational challenges.

Balance Sheet

The company's balance sheet shows moderate leverage with a debt-to-equity ratio of 0.56, indicating manageable debt levels. The equity ratio of 31% implies a healthy equity base relative to total assets. However, return on equity is negative due to losses, which is a potential risk.

Cash Flow

Operating cash flow remains robust, though it has decreased compared to the previous year. Free cash flow also decreased by 48.9%, but the company maintains a positive free cash flow to net income ratio, signaling efficient cash management despite net losses. The operating cash flow to net income ratio is strong, suggesting effective cash conversion from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	469.33M	453.27M	454.71M	406.33M	355.59M	431.45M
Gross Profit	128.49M	165.26M	166.96M	394.72M	341.52M	417.67M
EBITDA	79.80M	77.11M	95.68M	92.32M	43.96M	255.36M
Net Income	2.93M	-5.07M	-9.57M	-20.61M	-68.81M	125.72M
Balance Sheet
Total Assets	585.70M	564.46M	611.04M	561.35M	570.96M	669.04M
Cash, Cash Equivalents and Short-Term Investments	190.92M	236.67M	193.66M	177.53M	127.53M	234.34M
Total Debt	89.23M	68.65M	106.57M	40.11M	65.01M	115.07M
Total Liabilities	405.37M	373.26M	416.65M	357.47M	347.75M	376.15M
Stockholders Equity	175.09M	185.85M	189.33M	199.77M	219.58M	289.37M
Cash Flow
Free Cash Flow	45.57M	134.94M	64.08M	125.52M	-29.55M	121.64M
Operating Cash Flow	69.33M	151.09M	78.66M	139.82M	51.31M	123.88M
Investing Cash Flow	-17.44M	-50.50M	8.16M	-13.17M	-79.96M	-2.85M
Financing Cash Flow	-69.01M	-66.24M	-70.60M	-77.31M	-78.46M	-77.89M

Modern Healthcare Technology Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0919, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.09, and above the 200-day MA of 0.09, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 61.91 is Neutral, neither overbought nor oversold. The STOCH value of 66.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0919.

Modern Healthcare Technology Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8603	72 Outperform	HK$1.16B	25.35	54.98%	―	45.40%	12.38%
6966	64 Neutral	HK$550.00M	51.40	4.32%	1.00%	-24.33%	-45.69%
0922	62 Neutral	HK$353.20M	6.91	5.43%	3.14%	-16.88%	-11.54%
Sector *	56 Neutral	HK$25.31B	4.75	-2.69%	5.60%	-0.46%	-53.17%
0919	56 Neutral	€89.54M	24.38	-2.50%	―	-0.31%	47.17%
1827	51 Neutral	HK$424.00M	40.00	7.45%	―	-18.43%	―
8296	49 Neutral	HK$38.74M	―	-7.04%	―	0.98%	-4.81%

Modern Healthcare Technology Holdings Limited Corporate Events

Modern Healthcare Technology Holdings Announces 2025 AGM Agenda

Modern Healthcare Technology Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for August 28, 2025, in Hong Kong. Key agenda items include the adoption of financial statements, re-election of directors, re-appointment of KPMG as auditors, and authorization for the board to manage share allotments. These resolutions, if passed, will influence the company’s governance and financial strategies, potentially impacting its market position and shareholder value.

Modern Healthcare Technology Updates Nomination Committee Terms

Modern Healthcare Technology Holdings Limited has updated the terms of reference for its Nomination Committee, which is responsible for advising the board on its composition and succession planning. This update aims to ensure a diverse and effective board structure, with a requirement for gender diversity among its members, potentially impacting the company’s governance and strategic direction.

Modern Healthcare Technology Holdings Limited Reports Annual Results for FY2025

Modern Healthcare Technology Holdings Limited announced its annual results for the fiscal year ending March 31, 2025. The company reported a slight decrease in revenue to HK$453,274,000 from the previous year, with a net loss of HK$4,771,000, though showing an improvement from the previous year’s loss. The results reflect challenges in managing costs and market conditions, impacting profitability. Despite these challenges, the company managed to reduce its loss, indicating potential stabilization in its operations.

Modern Healthcare Technology Announces Upcoming Board Meeting

Modern Healthcare Technology Holdings Limited has announced a board meeting scheduled for June 25, 2025, in Hong Kong. The meeting will address the approval of the company’s annual results for the financial year ending March 31, 2025, and the consideration of a dividend payment, which could impact the company’s financial strategy and shareholder returns.